SE7408892L - - Google Patents

Info

Publication number
SE7408892L
SE7408892L SE7408892A SE7408892A SE7408892L SE 7408892 L SE7408892 L SE 7408892L SE 7408892 A SE7408892 A SE 7408892A SE 7408892 A SE7408892 A SE 7408892A SE 7408892 L SE7408892 L SE 7408892L
Authority
SE
Sweden
Application number
SE7408892A
Inventor
B Laundon
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of SE7408892L publication Critical patent/SE7408892L/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
SE7408892A 1973-07-06 1974-07-05 SE7408892L (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3227373A GB1472534A (en) 1973-07-06 1973-07-06 7beta-hydroxyiminoacylamido-cephalosporins

Publications (1)

Publication Number Publication Date
SE7408892L true SE7408892L (xx) 1975-01-07

Family

ID=10336049

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7408892A SE7408892L (xx) 1973-07-06 1974-07-05

Country Status (16)

Country Link
US (1) US4007174A (xx)
JP (1) JPS5069093A (xx)
AT (1) AT335061B (xx)
BE (1) BE817304A (xx)
CA (1) CA1055016A (xx)
CH (1) CH615436A5 (xx)
DE (1) DE2432415A1 (xx)
DK (1) DK360874A (xx)
ES (1) ES428015A1 (xx)
FR (1) FR2235696B1 (xx)
GB (1) GB1472534A (xx)
IE (1) IE39595B1 (xx)
LU (1) LU70477A1 (xx)
NL (1) NL7409179A (xx)
SE (1) SE7408892L (xx)
ZA (1) ZA744349B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092477A (en) * 1971-05-14 1978-05-30 Glaxo Laboratories Limited 7β-[2-Etherified oximino-2-(phenyl- or naphthylacetamido)] cephalosporins
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
US4165429A (en) * 1976-06-28 1979-08-21 Yamanouchi Pharmaceutical Co., Ltd. 7α-METHOXY-CEPHALOSPORANIC ACID DERIVATIVES
GB1592149A (en) * 1976-10-08 1981-07-01 Fujisawa Pharmaceutical Co 3 7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for preparation thereof
SE439312B (sv) * 1977-03-25 1985-06-10 Roussel Uclaf Sett att framstella nya oximderivat av 3-acetoximetyl-7-aminotiazolylacetamido cefalosporansyra
US5574154A (en) * 1994-09-29 1996-11-12 Alnejma Bulk Pharmaceutical Co. A.B.P.C. Process for the preparation of cephalosporanic compounds
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE311519B (xx) * 1962-12-14 1969-06-16 Astra Ab
GB1208015A (en) * 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) * 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
GB1389194A (en) * 1971-01-29 1975-04-03 Glaxo Lab Ltd Antibiotics
GB1433141A (en) * 1972-07-07 1976-04-22 Glaxo Lab Ltd Antibiotics

Also Published As

Publication number Publication date
IE39595L (en) 1975-01-06
ATA556074A (de) 1976-06-15
AT335061B (de) 1977-02-25
FR2235696B1 (xx) 1976-12-24
US4007174A (en) 1977-02-08
NL7409179A (nl) 1975-01-08
IE39595B1 (en) 1978-11-22
CH615436A5 (en) 1980-01-31
GB1472534A (en) 1977-05-04
JPS5069093A (xx) 1975-06-09
ZA744349B (en) 1975-07-30
CA1055016A (en) 1979-05-22
DK360874A (xx) 1975-03-03
FR2235696A1 (xx) 1975-01-31
DE2432415A1 (de) 1975-01-30
AU7072374A (en) 1976-01-08
ES428015A1 (es) 1976-07-16
BE817304A (fr) 1975-01-06
LU70477A1 (xx) 1976-05-31

Similar Documents

Publication Publication Date Title
AR201758A1 (xx)
AU476761B2 (xx)
AU465372B2 (xx)
AR201235Q (xx)
AR201231Q (xx)
AU474593B2 (xx)
AU474511B2 (xx)
FR2235696B1 (xx)
AU474838B2 (xx)
AU465453B2 (xx)
AU471343B2 (xx)
AU465434B2 (xx)
AU450229B2 (xx)
AU476714B2 (xx)
FR2355849B1 (xx)
AR201229Q (xx)
AU472848B2 (xx)
AU466283B2 (xx)
AU476696B2 (xx)
AR199451A1 (xx)
FR2245360B1 (xx)
AU477823B2 (xx)
AR200885A1 (xx)
AR197627A1 (xx)
AU447540B2 (xx)